12/2
07:30 am
zvra
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Low
Report
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
11/20
04:37 pm
zvra
Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]
Medium
Report
Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]
11/20
04:31 pm
zvra
Zevra Therapeutics announces CFO transition [Seeking Alpha]
Medium
Report
Zevra Therapeutics announces CFO transition [Seeking Alpha]
11/20
04:05 pm
zvra
Zevra Therapeutics, Inc. Announces CFO Transition
Medium
Report
Zevra Therapeutics, Inc. Announces CFO Transition
11/8
09:35 am
zvra
Analysts Have Lowered Expectations For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Latest Results [Yahoo! Finance]
Low
Report
Analysts Have Lowered Expectations For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Latest Results [Yahoo! Finance]
11/6
11:04 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) was given a new $24.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) was given a new $24.00 price target on by analysts at Canaccord Genuity Group Inc..
11/6
10:02 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) had its price target lowered by analysts at Cantor Fitzgerald from $29.00 to $24.00. They now have an "overweight" rating on the stock.
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) had its price target lowered by analysts at Cantor Fitzgerald from $29.00 to $24.00. They now have an "overweight" rating on the stock.
11/6
12:10 am
zvra
Zevra Therapeutics Inc (ZVRA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Zevra Therapeutics Inc (ZVRA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/5
04:05 pm
zvra
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
Medium
Report
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
10/29
07:30 am
zvra
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
Medium
Report
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
10/27
07:30 am
zvra
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
Medium
Report
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
10/20
01:04 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by analysts at
Wall Stre
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by analysts at
Wall Stre
10/14
12:17 pm
zvra
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
10/12
01:08 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by analysts at
Wall Street
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by analysts at
Wall Street
10/6
06:03 pm
zvra
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/6
05:51 pm
zvra
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/6
01:18 pm
zvra
Zevra Therapeutics Stock Sees Healthy RS Rating Jump To 73 [Yahoo! Finance]
Medium
Report
Zevra Therapeutics Stock Sees Healthy RS Rating Jump To 73 [Yahoo! Finance]
10/4
03:06 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by analysts at
Wall Stre
Medium
Report
Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by analysts at
Wall Stre
10/3
03:48 pm
zvra
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
9/28
07:17 am
zvra
Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? [Yahoo! Finance]
Low
Report
Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? [Yahoo! Finance]
9/25
10:38 am
zvra
Zevra Therapeutics rises amid takeover speculation [Seeking Alpha]
Low
Report
Zevra Therapeutics rises amid takeover speculation [Seeking Alpha]
9/19
02:04 am
zvra
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C [Yahoo! Finance]
Medium
Report
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C [Yahoo! Finance]
9/18
07:30 am
zvra
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyr
Medium
Report
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyr
9/14
03:55 am
zvra
Do Zevra Therapeutics' (ZVRA) New MIPLYFFA Data Reshape the Rare Disease Innovation Narrative? [Yahoo! Finance]
Medium
Report
Do Zevra Therapeutics' (ZVRA) New MIPLYFFA Data Reshape the Rare Disease Innovation Narrative? [Yahoo! Finance]